Calliditas Therapeutics: First patient randomized in pivotal TRANSFORM study with setanaxib

STOCKHOLM, Feb. 15, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the first patient has been randomized in the company's

Related Keywords

Sweden ,Stockholm ,Marie Galay ,Exchange Commission ,Trial Press ,European Medicines Agency ,Nasdaq Stockholm ,Track Designation ,Nasdaq Global Select Market ,Kidney Disease ,Private Securities Litigation Reform Act ,Patient Randomized ,Calliditas ,Herapeutics ,First ,Patient ,Randomized ,Pivotal ,Ransform ,Study ,Setanaxib ,